Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Lineage, Inc. common stock related to its July 2024 IPO, alleging that the registration statement was misleading and failed to disclose critical information about the company's financial health and market conditions [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and destocking of excessive inventory from the COVID-19 pandemic [5]. - It is alleged that Lineage implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The company reportedly failed to counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or declining revenue, occupancy rates, and rent prices [5]. Group 2: Investor Information - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by September 30, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - A class action lawsuit has been filed against XPLR Infrastructure, LP (formerly Nextera Energy Partners, LP) for misleading statements made during the Class Period from September 27, 2023, to January 27, 2025, potentially affecting investors' rights and financial interests [1][5]. Group 1: Lawsuit Details - The lawsuit claims that XPLR was struggling to maintain its operations as a yieldco, which focuses on delivering cash distributions to investors [5]. - Defendants allegedly made false statements and failed to disclose significant risks associated with financing arrangements that temporarily alleviated operational issues [5]. - The lawsuit asserts that XPLR's business model and distribution growth rate were unsustainable, leading to planned halts in cash distributions to investors [5]. Group 2: Investor Actions - Investors who purchased XPLR common units during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Reddit, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 18, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Reddit, Inc. for allegedly making false and misleading statements regarding user engagement and advertising revenues during the Class Period [4]. - The lawsuit claims that changes in Google Search's algorithm led to a significant reduction in traffic to Reddit, which was not disclosed by the defendants [4]. - Investors are encouraged to join the class action and can do so by contacting Rosen Law Firm for more information [2][5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, highlighting the firm's expertise in this area [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fiserv, Inc. common stock between July 24, 2024, and July 22, 2025, of the September 22, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1][2] Group 1: Class Action Details - A class action lawsuit has been filed against Fiserv, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Fiserv made false and misleading statements regarding its Clover platform and the forced migration of Payeezy merchants, which concealed a slowdown in new merchant business [4] Group 2: Allegations Against Fiserv - The lawsuit alleges that Fiserv's Clover platform experienced temporary revenue growth due to forced conversions from the Payeezy platform, masking underlying issues [4] - It is claimed that many former Payeezy merchants switched to competing solutions due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4] - The lawsuit asserts that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Replimune securities between November 22, 2024, and July 21, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].

Core Viewpoint - A lawsuit has been filed against Lineage, Inc. and its senior executives for potential violations of federal securities laws related to its IPO and subsequent financial performance [1][2]. Group 1: Lawsuit Details - Investors have until September 30, 2025, to request to lead the case, which is pending in the U.S. District Court for the Eastern District of Michigan [2]. - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, concerning investors who purchased stock during Lineage's IPO on July 25, 2024 [2]. Group 2: Company Overview - Lineage, Inc. operates as a cold storage-focused real estate investment trust (REIT), owning and managing temperature-controlled storage facilities for perishable products [3]. Group 3: Allegations Against Lineage - The IPO documents claimed strong cash flows due to consistent cold chain demand, suggesting resilience during economic stress, while the reality was a downturn as customers destocked excess inventory from the pandemic [4]. - Following the IPO, Lineage's stock price fell from an initial $78 per share to approximately $40 per share, indicating a significant decline in market confidence [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fiserv, Inc. common stock between July 24, 2024, and July 22, 2025, of the September 22, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by September 22, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against Fiserv - The lawsuit alleges that Fiserv made false and misleading statements regarding its Clover platform and the forced migration of Payeezy merchants [4] - It is claimed that Clover's revenue growth was artificially inflated due to these forced conversions, masking a slowdown in new merchant business [4] - The lawsuit further alleges that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4]

Core Insights - Sarepta Therapeutics announced a major restructuring involving a 36% workforce reduction, equating to 500 employees, aimed at saving approximately $400 million annually [1] - The FDA has mandated a black box warning for Sarepta's gene therapy drug, ELEVIDYS, due to risks of acute liver injury and acute liver failure [1] Legal Issues - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2][4] - The lawsuit alleges that Sarepta misled investors regarding the safety and efficacy of ELEVIDYS, claiming the company portrayed the drug as safe while withholding critical risk information [4][5] Safety Concerns - The lawsuit highlights that Sarepta failed to disclose significant safety risks associated with ELEVIDYS and inadequacies in clinical trial protocols [5] - A timeline of events indicates that Sarepta reported a patient death during a trial on March 18, 2025, followed by further disclosures of deaths and regulatory scrutiny [6][7][8] Regulatory Scrutiny - On July 25, 2025, the European Medicines Agency rejected ELEVIDYS due to questions about its effectiveness, leading to a further decline in Sarepta's stock price [9]

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy drug, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Group 1: Company Developments - The company reported the death of a third patient treated with ELEVIDYS, resulting in shares closing down $7.89 [1]. - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Group 2: Legal and Regulatory Issues - The lawsuit claims that Sarepta made false statements and failed to disclose critical information, particularly regarding patient safety updates that began on March 18, 2025 [5]. - Following the initial death report, Sarepta halted recruitment and dosing in some clinical studies as requested by EU authorities [6]. - Subsequent deaths of patients treated with ELEVIDYS led to further regulatory scrutiny, including a safety communication from the FDA regarding acute liver failure risks [8]. Group 3: Market Reactions and Analyst Opinions - The financial press reported that following the lawsuit, H.C. Wainwright reduced its price target for Sarepta to $0, reflecting a loss of confidence in the company's future prospects [10]. - The investigation by Hagens Berman is focused on whether Sarepta misled investors about the safety and revenue potential of its gene therapies [11].

SO WHAT: If you purchased Fiserv common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Fiserv class action, go to https://rosenlegal.com/submit-form/? case_id=42465 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no la ...